[{"id":"1f02bb00-f1cc-41ae-861d-71bd39144975","acronym":"VYP","url":"https://clinicaltrials.gov/study/NCT06715267","created_at":"2025-02-26T10:35:18.326Z","updated_at":"2025-02-26T10:35:18.326Z","phase":"","brief_title":"Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)","source_id_and_acronym":"NCT06715267 - VYP","lead_sponsor":"University Hospital, Brest","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2038","primary_completion_date":" 04/01/2038","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-12-04"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"6dcd86de-9151-4b21-9983-a57a1be5a9d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05025488","created_at":"2021-08-27T12:53:08.421Z","updated_at":"2024-07-02T16:35:14.494Z","phase":"Phase 1","brief_title":"Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm","source_id_and_acronym":"NCT05025488","lead_sponsor":"Marina Kremyanskaya","biomarkers":" CALR","pipe":" | ","alterations":" CALR mutation","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/04/2023","start_date":" 04/04/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-15"},{"id":"e1c26bff-16d7-4b47-8bbc-7cfb19350620","acronym":"","url":"https://clinicaltrials.gov/study/NCT03566446","created_at":"2021-01-21T20:52:51.690Z","updated_at":"2024-07-02T16:35:43.105Z","phase":"Phase 1","brief_title":"CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms","source_id_and_acronym":"NCT03566446","lead_sponsor":"Inge Marie Svane","biomarkers":" CALR","pipe":" | ","alterations":" CALR mutation","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CALR mutation"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 02/20/2020","primary_completion_date":" 02/20/2020","study_txt":" Completion: 04/30/2021","study_completion_date":" 04/30/2021","last_update_posted":"2023-07-13"},{"id":"bb338bc0-84a5-416d-9940-f963dcb3cec6","acronym":"FAST","url":"https://clinicaltrials.gov/study/NCT02611973","created_at":"2021-01-18T12:41:23.906Z","updated_at":"2024-07-02T16:37:19.528Z","phase":"Phase 3","brief_title":"Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia","source_id_and_acronym":"NCT02611973 - FAST","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F • CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 2250","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2017-07-26"}]